View Older Stories View More Recent Stories

Oct 26, 2018 09:35AM Anavex Life Sciences (AVXL) Highlights New Clinical Data for ANAVEX2-73 in Late-Breaking Oral Presentation at 2018 CTAD Meeting
Oct 26, 2018 09:30AM Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Oct 19, 2018 07:07AM Anavex Life Sciences (AVXL) Receives FDA Approval of IND for Phase 2 Trial of ANAVEX2-73 in Patients with Rett Syndrome
Oct 19, 2018 07:00AM Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome
Sep 26, 2018 07:00AM Anavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
Aug 28, 2018 07:08AM Anavex Life Sciences (AVXL) Reports First Patient Enrolled in Phase 2b/3 Clinical Trial of ANAVEX2-73 for Treatment of Early Alzheimer’s Disease
Aug 28, 2018 07:00AM First Patient Enrolled in Anavex Life Sciences Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease
Aug 9, 2018 07:00AM Anavex Life Sciences Reports Fiscal Third Quarter 2018 Financial Results
Aug 7, 2018 07:00AM Anavex Life Sciences to Announce Fiscal Third Quarter 2018 Financial Results on Thursday, August 9, 2018
Jul 25, 2018 09:00AM Anavex Life Sciences Presents New Data Identifying Treatment Response Biomarkers in Alzheimer’s Disease Patients Treated with Investigational ANAVEX®2-73 at 2018 Alzheimer’s Association Internati
Jul 9, 2018 07:03AM Anavex Life Sciences (AVXL) Granted Approval to Initiate Phase 2 Clinical Trial of ANAVEX2-73 for Treatment of Parkinson's Disease Dementia
Jul 9, 2018 07:00AM Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia
Jul 3, 2018 07:02AM Anavex Life Sciences (AVXL) Announces Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX 2-73 for Treatment of Early AD
Jul 3, 2018 07:00AM Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease
May 10, 2018 07:00AM Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results
May 9, 2018 07:00AM Anavex Life Sciences to Announce Fiscal Second Quarter 2018 Financial Results on Thursday, May 10, 2018
Apr 17, 2018 07:10AM Anavex Life Sciences (AVXL) Begins Phase 2 Study of ANAVEX2-73 in Parkinson’s Disease Dementia; Provides Clinical Study Update for ANAVEX2-73 in Rett Syndrome
Apr 17, 2018 07:08AM Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX®2-73 in Parkinson’s Disease Dementia and Provides Clinical Study Update for ANAVEX®2-73 in Rett Syndrome
Mar 9, 2018 07:00AM Anavex Life Sciences to Present at the 30th Annual ROTH Conference
Mar 7, 2018 07:00AM Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)
Mar 6, 2018 07:00AM Anavex Life Sciences to Present at Cowen and Company 38th Annual Health Care Conference
Mar 5, 2018 07:00AM Anavex Life Sciences Strengthens Management Team and Board of Directors
Feb 8, 2018 07:00AM Anavex Life Sciences to Present at the 2018 BIO CEO & Investor Conference
Feb 7, 2018 07:00AM Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results
Feb 5, 2018 07:00AM Anavex Life Sciences to Announce Fiscal First Quarter 2018 Financial Results and Provide an Update on Clinical Programs and Corporate Highlights on Wednesday, February 7, 2018
Jan 24, 2018 07:00AM Anavex Life Sciences to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference
Jan 16, 2018 07:06AM Anavex Life Sciences (AVXL) Announces Potential Normalization of Hypertension with ANAVEX2-73 Published in The Journal of Clinical Hypertension
Jan 16, 2018 07:00AM Anavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX®2-73 Published in The Journal of Clinical Hypertension
Dec 11, 2017 07:00AM Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs
Nov 21, 2017 07:06AM Anavex Life Sciences (AVXL) Says Newly Published Data on AD Research Demonstrate Neuroprotective Features of Sigma-1 Receptor
Nov 21, 2017 07:00AM Anavex Life Sciences Reports Newly Published Data on Alzheimer's Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor
Nov 8, 2017 07:00AM Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington, DC
Nov 4, 2017 03:30PM Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX®2-73 at 2017 Clinical Trials on Alzheimer’s Disease Meeting
Oct 30, 2017 07:08AM Anavex Life Sciences (AVXL) Presents Additional Data on ANAVEX2-73 at Conference
Oct 30, 2017 07:00AM Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson's Disease Therapeutics Conference
Oct 27, 2017 08:53AM Anavex Life Sciences (AVXL) Announces New Data Related to MS Presented at ECTRIMS-ACTRIMS Meeting
Oct 27, 2017 08:52AM Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017
Oct 12, 2017 07:13AM Anavex Life Sciences (AVXL) Reports PK and PD Data from Phase 2a Trial of ANAVEX 2-73 in Mild-to-Moderate AD
Oct 12, 2017 07:00AM Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients; Conference call today at 8:30am ET
Sep 21, 2017 07:00AM Anavex Life Sciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference
Sep 5, 2017 07:08AM Anavex Life Sciences (AVXL) Reports U.S. Patent for Composition of Matter Covering ANAVEX 2-73
Sep 5, 2017 07:00AM Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX™ 2-73
Aug 7, 2017 07:00AM Anavex Reports Fiscal Third Quarter 2017 Financial Results
Jul 20, 2017 07:00AM Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board
Jun 5, 2017 07:00AM Anavex Life Sciences to Present at Jefferies 2017 Global Healthcare Conference
May 22, 2017 07:09AM Anavex Life Sciences (AVXL) Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders
May 22, 2017 07:00AM Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome: Data Presented at Antiepileptic Drug Trials XIV 2017 Conference
May 10, 2017 07:00AM Anavex Reports Fiscal Second Quarter 2017 Financial Results
May 1, 2017 07:00AM Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President of Regulatory Affairs
Apr 3, 2017 07:17AM Anavex Life Sciences (AVXL) Reports New Mechanism of Action Data Related to ANAVEX Compounds Targeting Sigma-1 Receptor at AD/PD Meeting
View More Recent Stories View Older Stories